OncoMatch/Clinical Trials/NCT07078929
Clinical Trial of CMD63 Chimeric Antigen Receptor T-cell (CAR T-cell) in Children With Acute Lymphoblastic Leukemia (ALL)
Is NCT07078929 recruiting? Yes, currently enrolling (May 2026). This Phase 1 trial studies CD19-IL7Ra CAR-T cells for relapse b acute lymphoblastic leukemia.
Treatment: CD19-IL7Ra CAR-T cells — A Phase 1 clinical trial to evaluate the safety and early efficacy of Chimeric Antigen Receptor T-cell (CAR T-cell) with IL-7Rα signaling targeting CD19 in children with relapsed and refractory B-cell Acute Lymphoblastic Leukemia (ALL) after complete standard treatments.
Check if I qualifyExtracted eligibility criteria
Cancer type
Acute Lymphoblastic Leukemia
Biomarker criteria
Required: CD19 overexpression
The participant's disease must be CD19 positive either by immunohistochemistry or flow cytometry analysis
Prior therapy
Lab requirements
Kidney function
Creatinine less 5 times the upper limit of normal (ULN)
Liver function
AST (SGOT) less 5 times the upper limit of normal (ULN); ALT (SGPT) less 5 times the upper limit of normal (ULN); Total bilirubin less 3 times the upper limit of normal (ULN)
Normal organ function: AST (SGOT) less 5 times the upper limit of normal (ULN); ALT (SGPT) less 5 times the upper limit of normal (ULN); Total bilirubin less 3 times the upper limit of normal (ULN); Creatinine less 5 times the upper limit of normal (ULN); SpO2 room air greater than or equal to 90%
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify